Lexicon Pharma (LXRX) reported Q4 EPS of ($0.16), in-line with the analyst estimate of ($0.16). Revenue for the quarter came in at $37 thousand versus the consensus estimate of $50...
Investing.com – U.S. stocks were lower after the close on Thursday, as losses in the Technology, Consumer Goods and Consumer Services sectors led shares lower. At the close in...
Arena Pharmaceuticals ARNA announced that its phase IIb CULTIVATE study evaluating cannabinoid receptor 2 agonist candidate, olorinab, in patients with abdominal pain due to...
Axsome Therapeutics (NASDAQ:AXSM), Inc. AXSM incurred a loss of 78 cents per share in the fourth quarter of 2020, wider than the Zacks Consensus Estimate of a loss of 73 cents per...
Teladoc (NYSE:TDOC) Health, Inc. TDOC is set to report fourth-quarter earnings on Feb 24.The company is likely to report strong revenue outperformance for the fourth quarter,...
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its pipeline includes Sotagliflozin, LX9211, and LX2761. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes, heart failure and chronic kidney disease. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of sodium-glucose cotransporter 2 (SGLT2) in the kidney.
|Average||20.000 (+749.26% Upside)|
|No. of Analysts||1|